Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. - Wikidata - awgldk - TriplyDB

Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.

Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.

http://www.wikidata.org/entity/Q33420853

about

Induction of Regulatory T Cells by Intravenous Immunoglobulin: A Bridge between Adaptive and Innate Immunity Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies Desensitization: Overcoming the Immunologic Barriers to Transplantation Mechanisms of Autoantibody-Induced Pathology.Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs.Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy.Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats.Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.Protection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation.Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis.Differences in Anti-Inflammatory Actions of Intravenous Immunoglobulin between Mice and Men: More than Meets the Eye.Using glyco-engineering to produce therapeutic proteins.bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression.Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options.IVIG-mediated effector functions in autoimmune and inflammatory diseases.State-of-the-art technologies for rapid and high-throughput sample preparation and analysis of N-glycans from antibodies.The Emerging Importance of IgG Fab Glycosylation in Immunity.Sweet but dangerous - the role of immunoglobulin G glycosylation in autoimmunity and inflammation.Intravenous immunoglobulin: pharmacological properties and use in polyneuropathies.Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors.Regulation of antibody effector functions through IgG Fc N-glycosylation.Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy.Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering.Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities.Combining measurements to estimate properties and characterization extent of complex biochemical mixtures; applications to Heparan Sulfate.Translating Inhibitory Fc Receptor Biology into Novel Therapeutic Approaches.High-resolution physicochemical characterization of different intravenous immunoglobulin products.Unlocking the bone: Fcγ-receptors and antibody glycosylation are keys to connecting bone homeostasis to humoral immunity.Glycosynthase Mutants of Endoglycosidase S2 Show Potent Transglycosylation Activity and Remarkably Relaxed Substrate Specificity for Antibody Glycosylation Remodeling.Antibody production using a ciliate generates unusual antibody glycoforms displaying enhanced cell-killing activity.Evaluation of a glycoengineered monoclonal antibody via LC-MS analysis in combination with multiple enzymatic digestion.Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?Piperidine-based glycodendrons as protein N-glycan prosthetics.Pro-inflammatory State in Monoclonal Gammopathy of Undetermined Significance and in Multiple Myeloma Is Characterized by Low Sialylation of Pathogen-Specific and Other Monoclonal Immunoglobulins.Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease.Solid-Phase Enzymatic Remodeling Produces High Yields of Single Glycoform Antibodies.Desensitisation strategies in high-risk children before kidney transplantation.Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?

P2860

Q26781290-31FB1A13-D660-42B6-9E53-AF2E67ECEE58 Q28069362-D97C790B-3907-471D-90F0-726E1CF533CD Q30397952-4397C0B1-2B9A-467F-ADC6-A0544021435D Q33740580-C4EAA2B8-4514-43FF-926D-EA4559A1BCAC Q35590264-2A252E66-F1DC-46D8-B1DE-D79D5AEDEF21 Q35803387-41EA57C4-7ABE-4D32-92F3-630B67E96D1F Q36125875-6ACB5F99-C3E2-474C-9DBA-9F4B5DA91DDB Q36239584-FF56EABB-1768-4D0E-9AE0-D68934D04CEC Q36266469-CBFD1112-8453-4414-8C43-8CD8283778D9 Q36592223-BB34B158-5487-49DB-8E04-67E066DC7173 Q36768842-63A44D6B-EE93-4178-8E87-9DF955940CC7 Q38478867-E860D312-E08E-4CF1-B556-832A7989C6D2 Q38547311-6B733A12-CED4-4C55-A4C2-060C1D8748B1 Q38615353-2FB870A1-E6C8-457C-BEF6-EDC0EDE90152 Q38695599-D9BDCC79-9BBD-42A7-9A25-091271399639 Q38699812-4B88A9D2-3AA9-427B-9BB0-0FDBDDA03CEB Q38717803-FBBB1631-2C4A-4BCE-BF31-A7996F772F62 Q38724772-1BF0CB77-3F17-418E-A87A-087ECCE575A3 Q38851112-F1EF48C1-2CFA-4AB9-ACD7-983A746E6618 Q38900642-A0D717B8-0A14-442E-AE22-44517DA4B3F3 Q38912355-554EDCFA-CF2A-432D-BA36-6CFE3AD981D8 Q38957490-1FA27D60-E744-4A52-89DB-04C9BB11E222 Q39062945-C208E80C-CB72-42D4-BFAE-2EBC66906A36 Q39279968-2C8062C2-934A-4206-B26E-FF960A29E3F5 Q40077073-50ED254D-D0B3-4A04-8F75-53733BF2CCFE Q40625483-584AA0CE-B0E8-4474-8D99-84AE84033E69 Q40762677-33E7C030-F80C-4C2B-B476-E2DFC88A8545 Q41185651-533CD374-0114-4CDF-BC36-037E4EE79A19 Q41787449-7A838362-2286-4AA1-8740-CEF9C89DFC84 Q41941555-681E2254-4B94-48C2-81FA-C4D21BBF1E0F Q42129626-12DB16FD-B47A-4982-914A-5C502A895213 Q42132914-F64BDD30-AACD-4075-BC76-3F92C9AD4739 Q42316355-9909F6BA-92E6-4FA3-960D-66D0FD0B83DF Q42375731-0CA23226-9F59-4E10-9A98-08DD505FC1B7 Q42387014-F382A6FC-1677-40F4-81BF-F71150F3FD13 Q47132349-CFC80DE5-8A09-42B4-ADB1-2228DE1F8C19 Q47220975-5AC2B04E-AEE5-4B35-BF85-7A8CD6E22862 Q47286747-AD0FF439-87EE-4C18-87A7-7FF7FC517B05 Q47563660-12F93819-CBBD-44F9-A3E1-3AE772124B14 Q47804590-0160D79C-C7EF-488B-8D7D-A7B286D3BF4B

P2860

Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.

http://www.wikidata.org/entity/Q33420853

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Controlled tetra-Fc sialylatio ...... ed anti-inflammatory activity.

@ast

Controlled tetra-Fc sialylatio ...... ed anti-inflammatory activity.

@en

type

label

Controlled tetra-Fc sialylatio ...... ed anti-inflammatory activity.

@ast

Controlled tetra-Fc sialylatio ...... ed anti-inflammatory activity.

@en

prefLabel

Controlled tetra-Fc sialylatio ...... ed anti-inflammatory activity.

@ast

Controlled tetra-Fc sialylatio ...... ed anti-inflammatory activity.

@en

P1433

Q33420853-DAA863AC-A610-44C7-B8CF-B07B40721D84

P1476

Q33420853-A5BB4FE2-422F-4FA8-960C-8E6C05F25E51

P2093

Q33420853-077F94EE-8FD3-40BD-9707-ECA8B1790CF9

Q33420853-094F17FD-DF71-4B7F-AC57-2C7E8BBBFE53

Q33420853-1E3B3248-E085-4817-9A84-1E6F64C23734

Q33420853-2CFC821A-0F9E-4CE0-B369-671155338B1C

Q33420853-33EB66DD-4C26-4CFA-A10B-4C9B1B05F2EC

Q33420853-34559137-6D58-4576-8DF8-FDAA98369774

Q33420853-3EE5DDA4-791A-44E0-AE40-E5A5783762B5

Q33420853-746665F5-6123-46C6-9447-6BC1A331D06B

Q33420853-B310C1B3-CEC6-45EE-9CCC-26EE43805A45

Q33420853-B5582898-6248-4E15-8FB1-69FA51A80A44

P2860

Q33420853-06A21F78-4574-4CF5-98EF-9098EA8B7847

Q33420853-138CAA52-5D9C-42FD-B8BE-0EE6C6A1D3E3

Q33420853-1814D7FA-4434-4926-948E-D53DA85D882D

Q33420853-24D9331E-D321-436E-93D5-8785397BC56E

Q33420853-2A47DC03-ECB2-4D67-BA40-E932E98817CB

Q33420853-3BAA807D-43DB-4602-99C3-7BC6CAF436CC

Q33420853-3C41C7CF-029C-471B-9F10-59A3EBAE9F5B

Q33420853-3CAC265E-BCE5-4136-9037-0D8709384890

Q33420853-41410198-1AEF-463B-AE1B-4784DF80EF74

Q33420853-4F24C7B8-14F4-4552-BFD9-99224F98DB65

P304

Q33420853-E396BCE3-F2A5-4FDC-AFF0-FE8710A50791

P31

Q33420853-38F8384C-1D9C-43A6-A66B-A69C5393AF2A

P356

Q33420853-21925B4E-AA47-4D57-880A-6E3C038A3CCF

P407

Q33420853-4F4DBCF0-BA6A-43A3-B9ED-F3077131470D

P433

Q33420853-0ECAAC3C-C69E-4F8B-9AF7-F705090860FC

P478

Q33420853-8997CF2A-508C-4A79-9C73-395C7EED8CD2

P50

Q33420853-16A23990-F544-4CA0-AC76-CA59D1AB472F

Q33420853-4A5BF9A2-459C-48D9-88D2-D9649A39C0A6

Q33420853-77210242-767D-45DC-B8E8-14328E70E263

P577

Q33420853-B2618938-21B7-4AF1-BBDC-CEEDDB88986D

P5875

Q33420853-F4ED54A3-341F-40F4-9F20-B45046AC5523

P698

Q33420853-6C09C7F8-8AF9-4C2D-B77E-5F29164EDF38

P921

Q33420853-1A8B5574-1236-4AF7-BAC5-20BFEAD8736B

P932

Q33420853-F4F0E191-0D6F-4A8A-90F4-F687B5E7374E

P356

PNAS.1422481112

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Controlled tetra-Fc sialylatio ...... ed anti-inflammatory activity.

@en

P2093

Amy Medeiros

http://www.w3.org/2001/XMLSchema#string

Anthony M Manning

http://www.w3.org/2001/XMLSchema#string

Birgit C Schultes

http://www.w3.org/2001/XMLSchema#string

Carlos J Bosques

http://www.w3.org/2001/XMLSchema#string

Daniel Ortiz

http://www.w3.org/2001/XMLSchema#string

Divya Mekala

http://www.w3.org/2001/XMLSchema#string

Edward Cochran

http://www.w3.org/2001/XMLSchema#string

Ganesh V Kaundinya

http://www.w3.org/2001/XMLSchema#string

Hetal Sarvaiya

http://www.w3.org/2001/XMLSchema#string

Inessa Schwab

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases. A historical review

A close look at human IgG sialylation and subclass distribution after lectin fractionation

Development and characterization of novel erythropoiesis stimulating protein (NESP)

Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity.

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity.

Guidelines on the use of intravenous immune globulin for hematologic conditions.

Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin.

P304

E1297-306

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1422481112

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Falk Nimmerjahn

Jonathan C Lansing

P577

2015-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273156437

http://www.w3.org/2001/XMLSchema#string

P698

25733881

http://www.w3.org/2001/XMLSchema#string

P921

P932

4371931

http://www.w3.org/2001/XMLSchema#string